Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season

doi:10.1128/AAC.44.2.462-466.2000

This Article

	Full Text
	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager
	Reprints and Permissions
	Copyright Information
	Books from ASM Press
	MicrobeWorld

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Jones, M. E.
	Articles by Schmitz, F.-J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Jones, M. E.
	Articles by Schmitz, F.-J.

Previous Article | Next Article

Antimicrobial Agents and Chemotherapy, February 2000, p. 462-466, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season

Mark E. Jones,¹^,^* Daniel F. Sahm,² Nele Martin,³ Sibylle Scheuring,³ Peter Heisig,⁴ Clyde Thornsberry,² Karl Köhrer,³ and Franz-Josef Schmitz³

MRL Pharmaceutical Services, Utrecht, The Netherlands¹; MRL Pharmaceutical Services, Herndon, Virginia²; and Institute for Medical Microbiology and Virology, Heinrich-Heine University Düsseldorf, Düsseldorf,³ and Institute of Pharmaceutical Microbiology, University of Bonn, Bonn,⁴ Germany

Received 2 July 1999/Returned for modification 3 September 1999/Accepted 16 November 1999

From 8,419 worldwide clinical isolates of Streptococcus pneumoniae obtained during 1997-1998, 69 isolates with reduced susceptibilityor resistance to fluoroquinolones (FQs) were molecularly characterized.For the isolates in this prevalence study, only parC (Ser-79 $right-arrow$ Tyr)and gyrA (Ser-81 $right-arrow$ Phe or Tyr) mutations, especially in combination,were found to contribute significantly to resistance. These mutationsinfluenced the FQ MICs to varying degrees, although the rank orderof activity remains independent of mutation type, with ciprofloxacinthe least active, followed by levofloxacin, gatifloxacin/grepafloxacin/moxifloxacin/sparfloxacin/trovafloxacin,and clinafloxacin/sitafloxacin. Efflux likely plays a crucialrole in reduced susceptibility for new hydrophilicFQs.

^* Corresponding author. Mailing address: MRL Pharmaceutical Services, Den Brielstraat 11, 3554XD, Utrecht, The Netherlands.Phone: 31 30 265 1794. Fax: 31 30 265 1784. E-mail: mjones{at}thetsn.com.

Antimicrobial Agents and Chemotherapy, February 2000, p. 462-466, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

Avrain, L., Garvey, M., Mesaros, N., Glupczynski, Y., Mingeot-Leclercq, M.-P., Piddock, L. J. V., Tulkens, P. M., Vanhoof, R., Van Bambeke, F. (2007). Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. J Antimicrob Chemother 60: 965-972 [Abstract] [Full Text]
Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]
LaPlante, K. L., Rybak, M. J., Tsuji, B., Lodise, T. P., Kaatz, G. W. (2007). Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob. Agents Chemother. 51: 1315-1320 [Abstract] [Full Text]
Rozen, D. E., McGee, L., Levin, B. R., Klugman, K. P. (2007). Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 412-416 [Abstract] [Full Text]
Touyama, M., Higa, F., Nakasone, C., Shinzato, T., Akamine, M., Haranaga, S., Tateyama, M., Nakasone, I., Yamane, N., Fujita, J. (2006). In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 58: 1279-1282 [Abstract] [Full Text]
Ip, M., Chau, S. S. L., Chi, F., Qi, A., Lai, R. W. M. (2006). Rapid Screening of Fluoroquinolone Resistance Determinants in Streptococcus pneumoniae by PCR-Restriction Fragment Length Polymorphism and Single-Strand Conformational Polymorphism.. J. Clin. Microbiol. 44: 970-975 [Abstract] [Full Text]
Davies, T. A., Yee, Y. C., Goldschmidt, R., Bush, K., Sahm, D. F., Evangelista, A. (2006). Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother 57: 437-442 [Abstract] [Full Text]
Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]
Reinert, R. R., Reinert, S., van der Linden, M., Cil, M. Y., Al-Lahham, A., Appelbaum, P. (2005). Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003. Antimicrob. Agents Chemother. 49: 2903-2913 [Abstract] [Full Text]
Sadowy, E., Izdebski, R., Skoczynska, A., Gniadkowski, M., Hryniewicz, W. (2005). High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland. Antimicrob. Agents Chemother. 49: 2126-2129 [Abstract] [Full Text]
Jimenez, M. R. M., Bellido, J. L. M., Garcia Rodriguez, J. A. (2005). Risk Factors Associated with Colonization by Pneumococci with Reduced Susceptibility to Fluoroquinolones in Adult Outpatients. J. Clin. Microbiol. 43: 1193-1197 [Abstract] [Full Text]
Brown, S. D., Farrell, D. J., Morrissey, I. (2004). Prevalence and Molecular Analysis of Macrolide and Fluoroquinolone Resistance among Isolates of Streptococcus pneumoniae Collected during the 2000-2001 PROTEKT US Study. J. Clin. Microbiol. 42: 4980-4987 [Abstract] [Full Text]
Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N. (2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother. 48: 2049-2055 [Abstract] [Full Text]
Fluit, A. C., Schmitz, F.-J., Verhoef, J., Milatovic, D. (2004). In Vitro Activity of Daptomycin against Gram-Positive European Clinical Isolates with Defined Resistance Determinants. Antimicrob. Agents Chemother. 48: 1007-1011 [Abstract] [Full Text]
Davies, T. A., Goldschmidt, R., Pfleger, S., Loeloff, M., Bush, K., Sahm, D. F., Evangelista, A. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 52: 168-175 [Abstract] [Full Text]
Price, L. B., Vogler, A., Pearson, T., Busch, J. D., Schupp, J. M., Keim, P. (2003). In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin. Antimicrob. Agents Chemother. 47: 2362-2365 [Abstract] [Full Text]
Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]
Zhanel, G. G., Palatnick, L., Nichol, K. A., Bellyou, T., Low, D. E., Hoban, D. J. (2003). Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47: 1867-1874 [Abstract] [Full Text]
Johnson, C. N., Benjamin, W. H. Jr., Moser, S. A., Hollingshead, S. K., Zheng, X., Crain, M. J., Nahm, M. H., Waites, K. B. (2003). Genetic Relatedness of Levofloxacin-Nonsusceptible Streptococcus pneumoniae Isolates from North America. J. Clin. Microbiol. 41: 2458-2464 [Abstract] [Full Text]
Ruiz, J. (2003). Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51: 1109-1117 [Abstract] [Full Text]
Decousser, J.-W., Pina, P., Picot, F., Delalande, C., Pangon, B., Courvalin, P., Allouch, P., the ColBVH study group, (2003). Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother 51: 1213-1222 [Abstract] [Full Text]
Bui, M.-H., Stone, G. G., Nilius, A. M., Almer, L., Flamm, R. K. (2003). PCR-Oligonucleotide Ligation Assay for Detection of Point Mutations Associated with Quinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 1456-1459 [Abstract] [Full Text]
Mazzariol, A., Zuliani, J., Cornaglia, G., Rossolini, G. M., Fontana, R. (2002). AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp.. Antimicrob. Agents Chemother. 46: 3984-3986 [Abstract] [Full Text]
Madaras-Kelly, K. J., Daniels, C., Hegbloom, M., Thompson, M. (2002). Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50: 211-218 [Abstract] [Full Text]
Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I. A., Karginova, E., Thornsberry, C., Sahm, D. F. (2002). Longitudinal Assessment of Antipneumococcal Susceptibility in the United States. Antimicrob. Agents Chemother. 46: 2651-2655 [Abstract] [Full Text]
Houssaye, S., Gutmann, L., Varon, E. (2002). Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 2712-2715 [Abstract] [Full Text]
Jones, M. E., Critchley, I. A., Karlowsky, J. A., Blosser-Middleton, R. S., Schmitz, F.-J., Thornsberry, C., Sahm, D. F. (2002). In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV. Antimicrob. Agents Chemother. 46: 1651-1657 [Abstract] [Full Text]
Valdezate, S., Vindel, A., Echeita, A., Baquero, F., Canto, R. (2002). Topoisomerase II and IV Quinolone Resistance-Determining Regions in Stenotrophomonas maltophilia Clinical Isolates with Different Levels of Quinolone Susceptibility. Antimicrob. Agents Chemother. 46: 665-671 [Abstract] [Full Text]
Brueggemann, A. B., Coffman, S. L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A., Flamm, R., Doern, G. V. (2002). Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46: 680-688 [Abstract] [Full Text]
Piddock, L. J. V., Johnson, M. M., Simjee, S., Pumbwe, L. (2002). Expression of Efflux Pump Gene pmrA in Fluoroquinolone-Resistant and -Susceptible Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 808-812 [Abstract] [Full Text]
Schmitz, F.-J., Boos, M., Mayer, S., Kohrer, K., Scheuring, S., C. Fluit, A. (2002). In Vitro Activities of Novel Des-Fluoro(6) Quinolone BMS-284756 against Mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Selected with Different Quinolones. Antimicrob. Agents Chemother. 46: 934-935 [Full Text]
Davies, T. A., Evangelista, A., Pfleger, S., Bush, K., Sahm, D. F., Goldschmidt, R. (2002). Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46: 119-124 [Abstract] [Full Text]
Weigel, L. M., Anderson, G. J., Facklam, R. R., Tenover, F. C. (2001). Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3517-3523 [Abstract] [Full Text]
Fass, R. J., Barnishan, J. (2001). Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. J Antimicrob Chemother 48: 609-615 [Abstract] [Full Text]
Fluit, A. C., Visser, M. R., Schmitz, F.-J. (2001). Molecular Detection of Antimicrobial Resistance. Clin. Microbiol. Rev. 14: 836-871 [Abstract] [Full Text]
Ince, D., Hooper, D. C. (2001). Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2755-2764 [Abstract] [Full Text]
Alou, L., Ramirez, M., Garcia-Rey, C., Prieto, J., de Lencastre, H. (2001). Streptococcus pneumoniae Isolates with Reduced Susceptibility to Ciprofloxacin in Spain: Clonal Diversity and Appearance of Ciprofloxacin-Resistant Epidemic Clones. Antimicrob. Agents Chemother. 45: 2955-2957 [Abstract] [Full Text]
Nagai, K., Davies, T. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2001). Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 48: 365-374 [Abstract] [Full Text]
Bast, D. J., de Azavedo, J. C. S., Tam, T. Y., Kilburn, L., Duncan, C., Mandell, L. A., Davidson, R. J., Low, D. E. (2001). Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 2631-2634 [Abstract] [Full Text]
Hsueh, P.-R., Teng, L.-J., Wu, T.-L., Ho, S.-W., Luh, K.-T. (2001). First clinical isolate of Streptococcus pneumoniae exhibiting high-level resistance to fluoroquinolones in Taiwan. J Antimicrob Chemother 48: 316-317 [Full Text]
Friedman, S. M., Lu, T., Drlica, K. (2001). Mutation in the DNA Gyrase A Gene of Escherichia coli That Expands the Quinolone Resistance-Determining Region. Antimicrob. Agents Chemother. 45: 2378-2380 [Abstract] [Full Text]
Fukuda, H., Kishii, R., Takei, M., Hosaka, M. (2001). Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1649-1653 [Abstract] [Full Text]
Ho, P. L., Yam, W. C., Que, T. L., Tsang, D. N. C., Seto, W. H., Ng, T. K., Ng, W. S. (2001). Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J Antimicrob Chemother 47: 655-658 [Abstract] [Full Text]
Sahm, D. F., Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Mauriz, Y., Kahn, J. (2001). Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis. Antimicrob. Agents Chemother. 45: 1037-1042 [Abstract] [Full Text]
Boos, M., Mayer, S., Fischer, A., Köhrer, K., Scheuring, S., Heisig, P., Verhoef, J., Fluit, A. C., Schmitz, F.-J. (2001). In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 938-942 [Abstract] [Full Text]
Janoir, C., Varon, E., Kitzis, M.-D., Gutmann, L. (2001). New Mutation in ParE in a Pneumococcal In Vitro Mutant Resistant to Fluoroquinolones. Antimicrob. Agents Chemother. 45: 952-955 [Abstract] [Full Text]
Blondeau, J. M., Zhao, X., Hansen, G., Drlica, K. (2001). Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 433-438 [Abstract] [Full Text]
Bast, D. J., Low, D. E., Duncan, C. L., Kilburn, L., Mandell, L. A., Davidson, R. J., de Azavedo, J. C. S. (2000). Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae: Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance. Antimicrob. Agents Chemother. 44: 3049-3054 [Abstract] [Full Text]
Jones, M. E., Staples, A. M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H. D., Sahm, D. F. (2000). Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States. Antimicrob. Agents Chemother. 44: 2645-2652 [Abstract] [Full Text]

Clin. Vaccine Immunol.	Clin. Microbiol. Rev.
J. Clin. Microbiol.	ALL ASM JOURNALS